Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a responseguided therapy strategy

BACKGROUND Models for predicting hepatitis B e antigen(HBeAg)seroconversion in patients with HBeAg-positive chronic hepatitis B(CHB)after nucleos(t)ide analog treatment are rare.AIM To establish a simple scoring model based on a response-guided therapy(RGT)strategy for predicting HBeAg seroconversion and hepatitis B surface antigen(HBsAg)clearance.METHODS In this study,75 previously treated patients with HBeAg-positive CHB underwent a 52-week peginterferon-alfa(PEG-IFNα)treatment and a 24-wk follow-up.Logistic regression analysis was used to assess parameters at baseline,week 12,and week 24 to predict HBeAg seroconversion at 24 wk post-treatment.The two best predictors at each time point were used to establish a prediction model for PEG-IFNαtherapy efficacy.Parameters at each time point that met the corresponding optimal cutoff thresholds were scored as 1 or 0.RESULTS The two most meaningful predictors were HBsAg≤1000 IU/mL and HBeAg≤3 S/CO at baseline,HBsAg≤600 IU/mL and HBeAg≤3 S/CO at week 12,and HBsAg≤300 IU/mL and HBeAg≤2 S/CO at week 24.With a total score of 0 vs 2 at baseline,week 12,and week 24,the response rates were 23.8%,15.2%,and 11.1%vs 81.8%,80.0%,and 82.4%,respectively,and the HBsAg clearance rates were 2.4%,3.0%,and 0.0%,vs 54.5%,40.0%,and 41.2%,respectively.CONCLUSION We successfully established a predictive model and diagnosis-treatment process using the RGT strategy to predict HBeAg and HBsAg seroconversion in patients with HBeAg-positive CHB undergoing PEG-IFNαtherapy.

E光联合调Q激光治疗雀斑的临床疗效分析

目的分析E光联合调Q激光治疗雀斑的临床疗效。方法对我院在2021年1月-2023年12月收治的102例雀斑患者进行回顾性分析,根据治疗方案不同将其分为3组,联合组31例,E光组35例,调Q组36例,联合组实施E光联合调Q激光治疗,E光组单独实施E光治疗,调Q组单独实施调Q激光治疗,分析3组患者临床相关数据。结果联合组患者治疗总有效率高于E光组、调Q组(χ^(2)=7.087,P=0.029);三组治疗后IEWL、角质层含水量指标均有统计学意义(P<0.05),联合组与E光组治疗后IEWL、角质层含水量指标无统计学意义(P>0.05);联合组与E光组治疗后IEWL指标低于调Q组,角质层含水量高于调Q组(P<0.05);联合组和E光组、调Q组不良反应总发生率无统计学意义(χ^(2)=3.740,P=0.154);联合组、E光组、调Q组总满意度具有统计学意义(χ^(2)=7.969,P=0.019)。结论E光联合调Q激光治疗雀斑在提高治疗效果、改善皮肤屏障功能和增加皮肤含水量方面具有优势,同时保持了与单独治疗相似的安全性水平,并且能够提高患者的总满意度。

Exercise-induced modulation of miR-149-5p and MMP9 in LPS-triggered diabetic myoblast ER stress: licorice glycoside E as a potential therapeutic target

Background:This study explores the relationship between endoplasmic reticulum(ER)stress and diabetes,particularly focusing on the impact of physical exercise on ER stress mechanisms and identifying potential therapeutic drugs and targets for diabetes-related sepsis.The research also incorporates traditional physical therapy perspectives,emphasizing the genomic insights gained from exercise therapy in disease management and prevention.Methods:Gene analysis was conducted on the GSE168796 and GSE94717 datasets to identify ER stress-related genes.Gene interactions and immune cell correlations were mapped using GeneCard and STRING databases.A screening of 2,456 compounds from the TCMSP database was performed to identify potential therapeutic agents,with a focus on their docking potential.Techniques such as luciferase reporter gene assay and RNA interference were used to examine the interactions between microRNA-149-5p and MMP9.Results:The study identified 2,006 differentially expressed genes and 616 miRNAs.Key genes like MMP9,TNF-α,and IL1B were linked to an immunosuppressive state.Licorice glycoside E demonstrated high affinity for MMP9,suggesting its potential effectiveness in treating diabetes.The constructed miRNA network highlighted the regulatory roles of MMP9,IL1B,IFNG,and TNF-α.Experimental evidence confirmed the binding of microRNA-149-5p to MMP9,impacting apoptosis in diabetic cells.Conclusion:The findings highlight the regulatory role of microRNA-149-5p in managing MMP9,a crucial gene in diabetes pathophysiology.Licorice glycoside E emerges as a promising treatment option for diabetes,especially targeting MMP9 affected by ER stress.The study also underscores the significance of physical exercise in modulating ER stress pathways in diabetes management,bridging traditional physical therapy and modern scientific understanding.Our study has limitations.It focuses on the microRNA-149-5p-MMP9 network in sepsis,using cell-based methods without animal or clinical trials.Despite strong in vitro findings,in vivo studies are needed to confirm licorice glycoside E’s therapeutic potential and understand the microRNA-149-5p-MMP9 dynamics in real conditions.

分阶段三联疗法联合益生菌对幽门螺旋杆菌胃炎患者的效果及其对COX-2和E-cadherin的影响

目的:探讨分阶段三联疗法联合益生菌在幽门螺旋杆菌(Hp)胃炎患者中的治疗效果及其对环氧化酶2(COX-2)和钙粘附蛋白E(E-cadherin)的影响。方法:选取92例幽门螺旋杆菌胃炎患者作为研究对象,按照治疗方式不同分为对照组与观察组,每组各46例。对照组采用分阶段三联疗法治疗;观察组联合益生菌治疗,两组患者均治疗两个疗程(31 d为1个疗程),比较两组患者胃肠激素、C反应蛋白(CRP)、白细胞计数(WBC)、COX-2、E-cadherin、Hp根除率及不良反应发生情况。结果:干预后,两组患者PGⅠ、PGⅡ及G-17均降低,且观察组低于对照组(P<0.05);PGR水平均升高,且观察组高于对照组(P<0.05);干预后,两组炎症反应减轻及COX-2、E-cadherin水平均降低,且观察组低于对照组(P<0.05);疗程完毕后,观察组Hp根除率高于对照组(P<0.05);两组不良反应发生率无统计学差异(P>0.05)。结论:分阶段三联疗法联合益生菌用于Hp胃炎患者中,能调节胃肠激素,降低炎症反应和COX-2、E-cadherin水平,可提高Hp根除率,且药物安全性较高,值得推广应用。

Current and emerging pharmacological therapy for nonalcoholic fatty liver disease

The main treatment of patients with non-alcoholic fatty liver disease(NAFLD) is life style modification including weight reduction and dietary regimen.Majority of patients are safely treated with this management and pharmacologic interventions are not recommended. However, a subgroup of NAFLD patients with non-alcoholic steatohepatitis(NASH) who cannot achieve goals of life style modification may need pharmacological therapy. One major obstacle is measurement of histological outcome by liver biopsy which is an invasive method and is not recommended routinely in these patients. Several medications, mainly targeting baseline mechanism of NAFLD, have been investigated in clinical trials for treatment of NASH with promising results. At present, only pioglitazone acting as insulin sensitizing agent and vitamin E as an antioxidant have been recommended for treatment of NASH by international guidelines. Lipid lowering agents including statins and fibrates, pentoxifylline, angiotensin receptor blockers, ursodeoxycholic acid, probiotics and synbiotics are current agents with beneficial effects for treatment of NASH but have not been approved yet. Several emerging medications are in development for treatment of NASH. Obeticholic acid, liraglutide, elafibranor, cenicriviroc and aramchol have been tested in clinical trials or are completing trials. Here in, current and upcoming medications with promising results in clinical trial for treatment of NAFLD were reviewed.

Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review

BACKGROUND Ameloblastomas are common benign epithelial odontogenic neoplasms that present an aggressive and unpredictable behavior that may modify treatment strategies.Different signaling pathways that participate in the progression of these tumors have been identified.B-raf proto-oncogene serine/threonine kinase(BRAF)is a protein involved in the behavior of ameloblastomas,and it is related to many cell mechanisms.BRAF gene mutations have been identified in ameloblastomas,of which the BRAF V600E(valine substituted by glutamic acid at amino acid 600)mutation has been the most common and can be present concomitantly with other mutations that may be involved in its behavior.Targeted therapies have been used as an alternative in the case of resistance or contraindications to conventional treatments.AIM To document the presence of BRAF V600E and additional mutations,their behavior,and targeted therapies in these tumors.METHODS An electronic literature search was conducted according to PRISMA guidelines in PubMed/MEDLINE,Cochrane,EMBASE,and SpringerLink using the terms“ameloblastomas”,“BRAF V600E”,“additional mutations”,and“targeted therapies”.Ameloblastomas were classified according to WHO guidelines.Inclusion criteria were articles in English,published not more than 10 years ago,and studies with laboratory works related to BRAF V600E.Articles were evaluated by two independent reviewers and retrieved for full-text evaluation.The EBLIP Critical Appraisal Checklist was used to evaluate the quality of the eligible studies.Descriptive statistical analysis was performed.RESULTS Two independent reviewers,with a substantial concordance indicated by a kappa coefficient of k=0.76,evaluated a total of 19 articles that were included in this study.The analysis registered 521 conventional ameloblastomas(AM),81 unicystic ameloblastomas(UA),13 ameloblastic carcinomas(AC),three metastatic ameloblastomas(MA),and six peripheral ameloblastomas(PA),of which the histopathological type,anatomic location,laboratory tests,expression of BRAF mutation,and additional mutations were registered.The BRAF V600E mutation was found in 297 AM(57%),63 UA(77.7%),3 AC(23%),1 MA(50%),and 5 PA(83.3%).Follicular type predominated with a total of 116 cases(40%),followed by plexiform type with 63 cases(22.1%).Furthermore,both types presented additional mutations,in which alterations in JAK3 P132T,SMARCB1,PIK3CA,CTNNB1,SMO,and BRAF G606E genes were found.Four case reports were found with targeted therapy to BRAF V600E.CONCLUSION The identification of BRAF V600E and additional mutations as an aid in targeted therapies has been a breakthrough in alternative treatments of ameloblastomas where surgical treatments are contraindicated.

Vitamin E Therapy in Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is closely related to oxidative stress. Vitamin E (VE) is an effective antioxidant, which could relieve NAFLD symptoms by improving the balance of oxidation and anti-oxidation. However, recent researches indicate that the functional mechanisms of VE are not only limited to anti-oxidation, but also include adjusting the metabolism disorders of glucose and lipid. Furthermore, the efficacy of VE remains controversial in the treatment of NAFLD by far, and the suitable condition of patient, drug dosage, drug safety and course of treatment during clinical application still need to be discussed. Therefore, this paper reviewed the recent study progresses of clinical application of VE alone and VE and other drugs.

Effects of prostaglandin E combined with continuous renal replacement therapy on septic acute kidney injury

BACKGROUND The effects of prostaglandin E(PGE)combined with continuous renal replacement therapy(CRRT)on renal function and inflammatory responses in patients with septic acute kidney injury(SAKI)remain unclear.AIM To investigate the effects of PGE combined with CRRT on urinary augmenter of liver regeneration(ALR),urinary Na+/H+exchanger 3(NHE3),and serum inflammatory cytokines in patients with SAKI.METHODS The clinical data of 114 patients with SAKI admitted to Yichang Second People's Hospital from May 2017 to January 2019 were collected.Fifty-three cases treated by CRRT alone were included in a control group,while the other 61 cases treated with PGE combined with CRRT were included in an experimental group.Their urinary ALR,urinary NHE3,serum inflammatory cytokines,renal function indices,and immune function indices were detected.Changes in disease recovery and the incidence of adverse reactions were observed.The 28-d survival curve was plotted.RESULTS Before treatment,urinary ALR,urinary NHE3,blood urea nitrogen(BUN),serum creatinine(SCr),CD3+T lymphocytes,CD4+T lymphocytes,and CD4+/CD8+T lymphocyte ratio in the control and experimental groups were approximately the same.After treatment,urinary ALR and NHE3 decreased,while BUN,SCr,CD3+T lymphocytes,CD4+T lymphocytes,and CD4+/CD8+T lymphocyte ratio increased in all subjects.Urinary ALR,urinary NHE3,BUN,and SCr in the experimental group were significantly lower than those in the control group,while CD3+T lymphocytes,CD4+T lymphocytes,and CD4+/CD8+T lymphocyte ratio were significantly higher than those in the control group(P<0.05).After treatment,the levels of tumor necrosis factor-α,interleukin-18,and high sensitivity C-reactive protein in the experimental group were significantly lower than those in the control group(P<0.05).The time for urine volume recovery and intensive care unit treatment in the experimental group was significantly shorter than that in the control group(P<0.05),although there was no statistically significant difference in hospital stays between the two groups.The total incidence of adverse reactions did not differ statistically between the two groups.The 28-d survival rate in the experimental group(80.33%)was significantly higher than that in the control group(66.04%).CONCLUSION PGE combined with CRRT is clinically effective for treating SAKI,and the combination therapy can significantly improve renal function and reduce inflammatory responses.

Meso-substituted cationic 3-and 4-N-Pyridylporphyrins and their Zn(II)derivatives for antibacterial photodynamic therapy

Photodynamic inactivation of microorganisms known as antibacterial photodynamic therapy(APDT)is one of the most promising and innovative approaches for the destruction of pathogenic microorganisms.Among the photosensitizers(PSs),compounds based on cationic porphyrins/metalloporphyrins are most successfully used to inactivate microorganisms.Series of meso-substituted cationic pyridylporphyrins and metalloporphyrins with various peripheral groups in the third and fourth positions of the pyrrole ring have been synthesized in Armenia.The aim of this work was to determine and test the most e®ective cationic porphyrins and metalloporphyrins with high photoactivity against Gram negative and Gram positive microorganisms.It was shown that the synthesized cationic pyridylporphyrins/metalloporphyrins exhibit a high degree of phototoxicity towards both types of bacteria,including the methicillinresistant S.aureus strain.Zinc complexes of porphyrins are more phototoxic than metal-free porphyrin analogs.The e®ectiveness of these Zn–metalloporphyrins on bacteria is consistent with the level of singlet oxygen generation.It was found that the high antibacterial activity of the studied cationic porphyrins/metalloporphyrins depends on four factors:the presence in the porphyrin macrocycle of a positive charge(+4),a central metal atom(Zn2þÞand hydrophobic peripheral functional groups as well as high values of quantum yields of singlet oxygen.The results indicate that meso-substituted cationic pyridylporphyrins/metalloporphyrins cannd wider application in photoinactivation of bacteria than anionic or neutral PSs usually used in APDT.

EVALUATION OF NEUROPROTECTIVE EFFECTS OF LONG-TERM LOW DOSE HORMONE REPLACEMENT THERAPY ON POSTMENOPAUSAL WO-MEN BRAIN HIPPOCAMPUS USING MAGNETIC RESONANCE SCANNER

客观：在荷尔蒙在绝经后的女人上调查长期的低剂量荷尔蒙代替治疗(HRT ) 的效果水平，认知分数，马头鱼尾的怪兽体积，和磁性的回声光谱学(太太) 参数。方法：50-87 年的 182 个绝经后的女人的一个总数在北京联合医学院医院被选择并且分到 HRTgroup 和控制组。HRT 组的志愿者拿了低剂量荷尔蒙[estradiol (E2 ) 0.5-1.0 mg 和孕酮 0.5-2.0 mg，一次一天] 为 4-33 年。E2，孕酮，和睾丸激素的集中用连接酶的免疫吸着剂试金(ELISA ) 被测量。apolipoprotein E (ApoE ) 的 Thegene 类型被聚合酶链反应，和这些题目与 Alzheimer 的易受影响的基因(ApoE epsilon3/epsilon4 ) 测量“ s 疾病(广告) 被屏蔽。Theirhippocampus 卷和太太参数通过磁性的回声成像(MRI ) 被获得，并且在二个组的结果被统计方法分析。结果：与控制组相比，在在 HRT 的每个年龄阶段的 E2 的集中组织显著地更高(P 【 0.05 ) 除了 the80-89 岁亚群；然而，在在二个组之间的孕酮和睾丸激素的集中没有统计差别。在在二个组之间的 ApoEsubtypes 分发没有明显的差别。为有易受影响的基因 ApoE epsilon3/epsilon4 的题目的马头鱼尾的怪兽 MRI 的结果( HRT 组 14 盒子，控制组 11 盒子)证明到在 HRT 的整个大脑体积的双边的马头鱼尾的怪兽体积的比率组织( 0.406 +/- 0.028 )比控制组显著地高( 0.369 +/- 0.031 ， P 【 0.05 )。为有易受影响的基因 ApoE epsilon3/epsilon4 的题目的 1H 太太的结果( HRT 组 12 盒子，控制组 11 盒子)证明在在 HRT 组( 1.54 +/-0.08 )的马头鱼尾的怪兽的区域的 N-acetylaspartate/total 肌酸比控制组显著地高( 1.45 +/- 0.13 ， P 【 0.05 )。结论：Forpostmenopausalwomen，长期的低剂量 HRT 能在血浆维持 E2 的生理的集中。而且，与 ApoE epsilon3/epsilon4 基因在那些上执行的马头鱼尾的怪兽 MRI 证明长期的低剂量 HRT 能阻止马头鱼尾的怪兽萎缩，它是有益的维持大脑功能并且阻止广告。

The Paradoxical Effect of Paraquat on Leucyl-tRNA Levels in <i>E. coli</i>Provides New Insights for Amino Acid Therapy in Humans

Dihydroxyacid dehydratase (DHAD), the rate-limiting enzyme in the synthesis of branched-chain (BCA) amino acids in bacteria and plants, is sensitive to oxyradical toxicity. Oxidant stress reversibly inactivates DHAD and causes starvation for BCA and reversible cessation of growth in Escherichia coli [1][2]. To better understand the underlying toxicity mechanisms, we have determined the cellular concentrations of charged-tRNAs for BCA, in E. coli treated with the redox-active chemical, paraquat. Contrary to expectation, in the paraquat-treated cells, the concentration of only charged leucyl-tRNA decreased dramatically;whereas, the concentrations of the other BCAs (valine and isoleucine) increased. This paradoxical result, the “paraquat effect” can be best explained if leucine is the most abundant amino acid in the E. coli proteins and therefore the rate-limiting building block in their synthesis. Based on this assumption, we investigated the concentration of free amino acids in E. coli and their relative abundances in E. coli proteins. Protein amino acid frequencies were determined by analyzing one-hundred gene bank protein sequences with software developed as described in Methods. Leucine is the most abundant amino acid in the E. coli proteins (10%) and consequently, the cellular free leucine concentration is smaller and the native charged-leucyl-tRNA levels are much higher than those of valine and isoleucine. This has relevance to humans because: leucine-deprivation was shown to be beneficial in tumor suppression [3], and leucine-supplementation was beneficial in the recovery from exercise-induced muscle loss [4][5], and leucine also occurs at a higher frequency in almost all human proteins. In three human protein categories, we examined it ranged from 9% to 17%. This predominance of leucine in proteins would make cells vulnerable to impairment of the leucine pools and could explain our results in E. coli and some of the biological effects of free leucine in humans.

Effect of photodynamic therapy with(17R,18R)-2-(1-hexyloxyethyl)-2-devinyl chlorine E6 trisodium salt on pancreatic cancer cells in vitro and in vivo

AIM To investigate the antitumor effects and underlying mechanisms of(17 R,18 R)-2-(1-hexyloxyethyl)-2-devinyl chlorine E6 trisodium salt(YLG-1)-induced photodynamic therapy(PDT) on pancreatic cancer in vitro and in vivo.METHODS YLG-1 is a novel photosensitizer extracted from spirulina. Its phototoxicity, cellular uptake and localization, as well as its effect on reactive oxygen species(ROS) production, apoptosis, and expression of apoptosis-associated proteins were detected in vitro. An in vivo imaging system(IVIS), the Lumina K imaging system, and mouse models of subcutaneous Panc-1-bearing tumors were exploited to evaluate the drug delivery pathway and pancreatic cancer growth in vivo.RESULTS YLG-1 was localized to the mitochondria, and the appropriate incubation time was 6 h. Under 650 nm light irradiation, YLG-1-PDT exerted a potent cytotoxic effect on pancreatic cancer cells in vitro, which could be abolished by the ROS scavenger N-acetyl-L-cysteine(NAC). The death mode caused by YLG-1-PDT was apoptosis, accompanied by upregulated Bax and cleaved Caspase-3 and decreased Bcl-2 expression. The results from the IVIS images suggested that the optimal administration route was intratumoral(IT) injection and that the best time to conduct YLG-1-PDT was 2 h post-IT injection. Consistent with the results in vitro, YLG-1-PDT showed great growth inhibition effects on pancreatic cancer cells in a mouse model.CONCLUSION YLG-1 is a potential photosensitizer for pancreatic cancer PDT via IT injection, the mechanisms of which are associated with inducing ROS and promoting apoptosis.

耳穴埋针联合药物治疗小儿过敏性鼻炎-哮喘综合征的疗效观察及对肺功能和血清IgE、EOS、FeNO的影响

目的观察耳穴埋针联合药物治疗小儿过敏性鼻炎-哮喘综合征(combined allergic rhinitis and asthma syndrome,CARAS)的临床疗效及对肺功能和血清免疫球蛋白E(immunoglobulin E,IgE)、嗜酸性粒细胞(eosinophilic,EOS)、呼出气一氧化氮(fractional exhaled nitric oxide,FeNO)的影响。方法将84例CARAS患者随机分为观察组和对照组,每组42例。对照组予布地奈德雾化吸入,孟鲁司特钠睡前口服治疗;在此基础上观察组予耳穴埋针治疗。观察两组主要症状(鼻塞、鼻痒、喷嚏、清涕、气喘、胸闷、咳嗽、喉间痰鸣)积分、肺功能指标[(1秒用力呼气容积(forced expiratory volume in one second,FEV1)、用力肺活量(forced vital capacity,FVC)、FEV1/FVC、呼气峰流速(peak expiratory flow,PEF)]及血清Ig E、EOS和FeNO水平变化,并比较两组临床疗效。结果观察组总有效率为90.5%,与对照组的71.4%比较,差异有统计学意义(P<0.01)。治疗后,观察组主要症状积分均较治疗前改善,且治疗组优于对照组,差异有统计学意义(P<0.01)。治疗后,两组肺功能指标、血清Ig E、EOS和Fe NO水平与治疗前比较,差异均有统计学意义(P<0.01);且治疗组均优于对照组,差异有统计学意义(P<0.05)。结论耳穴埋针联合药物治疗小儿CARAS疗效显著,不仅能够改善患者鼻炎、哮喘症状,且能有效促进肺功能恢复,改善血清IgE、EOS和FeNO水平。

血清IL-10对慢性乙型肝炎患者抗病毒治疗后e抗原转阴的预测作用

目的观察慢性乙型肝炎病毒感染引起血清IL-10变化,探讨血清IL-10对慢性乙型肝炎(CHB)患者抗病毒治疗后e抗原(HBeAg)转阴的预测作用。方法纳入2008年5月—2013年9月于江苏省苏北人民医院和南京鼓楼医院就诊的90例CHB患者,包括6例非活动携带者(IC)、22例免疫耐受患者(IT)、44例HBeAg阳性患者(EPH)和18例HBeAg阴性患者(ENH)。同时,纳入11名健康人(HC)作为对照。对比健康人与CHB患者血清IL-10含量以及不同免疫状态的CHB患者IL-10血清含量。并对EPH患者中30例接受抗病毒治疗的患者进行随访,共5年。检测其抗病毒治疗后第0周、第4周、第12周、第24周和第48周血清ALT、HBV DNA和IL-10水平。观察抗病毒治疗后2年、3年和5年血清HBeAg是否转阴,并将其分为HBeAg转阴组和HBeAg仍阳性组,比较两组基线血清HBeAg和IL-10水平。结果CHB患者血清IL-10水平显著高于健康献血者。同时在CHB患者中,IT组、EPH组和ENH组患者血清IL-10含量明显高于IC组患者。抗病毒治疗后,血清ALT、HBV DNA、IL-10水平逐渐下降。通过随访发现,在抗病毒治疗后的2年、3年和5年内,分别有9人、10人、13人实现了HBeAg转阴。进一步分析发现,与HBeAg仍阳性组患者相比,在2年、3年和5年内实现HBeAg转阴的患者基线IL-10水平明显更高[(6.49±2.16)vs(3.33±1.22)pg/mL,P=0.062;(5.88±1.99)vs(2.27±1.36)pg/mL,P=0.026;(6.01±1.91)vs(1.15±0.63)pg/mL,P=0.027]。结论慢性乙型肝炎病毒感染可引起患者血清IL-10含量升高,抗病毒治疗可以降低血清IL-10含量,同时抗病毒治疗前血清IL-10含量较高的患者往往能够获得更好的治疗结局。

HLA-E基因表达沉默对人乳腺癌细胞生物学行为的影响

目的:探讨HLA-E基因表达对人乳腺癌细胞增殖、凋亡、侵袭、迁移等生物学行为的影响,分析靶向HLA-E基因的小分子RNA干扰(siRNA)技术应用于乳腺癌治疗的可行性。方法:设计并合成靶向HLA-E基因的特异性siRNA序列,转染至人乳腺癌细胞MDA-MB-231,同时设立空白对照组、阴性对照组及脂质体组。实时荧光定量PCR(qPCR)和Western blot法分别检测各组乳腺癌细胞HLA-E mRNA及蛋白的表达;CCK-8法和流式细胞术检测各组乳腺癌细胞增殖率和凋亡率;Transwell实验检测各组乳腺癌细胞侵袭和迁移能力。结果:乳腺癌细胞转染HLA-E siRNA后,HLA-E mRNA及蛋白表达水平明显降低。与阴性对照组相比,HLA-E siRNA转染组乳腺癌细胞增殖率降低(P<0.01);凋亡率增加(P<0.01);侵袭迁移能力降低(P<0.01)。结论:靶向人乳腺癌细胞HLA-E基因的siRNA能有效抑制其基因表达,进而抑制细胞增殖,诱导细胞凋亡,降低乳腺癌细胞侵袭和迁移能力。

EFFECT OF REPERFUSION THERAPY ON SOLUBLE CELL ADHESION MOLECULES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

Objective To observe the changes of serum soluble intercellular adhesion moiecuie type-1(ICAM-1) and E-selectin in patients with acute myocardial inlarction (AMI) receiving reperfusiontherapy. Methods Peripheral venous blood samples were taken from 21 patients with AMI before and4,8,12,24,48,72h after thrombolytic treatment or direct percutaneous transluminal coronary angioplasty (PTCA).Blood samples from 16 control subjects were drawn for one time. Serum concentration of ICAM-1 and E-selectinwas determined by double antibodies sandwich enzyme-linked immunosorbent assay. Results Serum levels ofICAM-1 and E-selectin were higher in patients with AMI than those in controls. Sixteen patients with AMIand successful roperfusion therapy had signifcantly reduction in serum concentration of ICAM-1 and E-selectinat 24 and 48h, but had a peak at 4h. The remaining live patients who failed in mperfusion theropy didn’t show anysignificant changes in these values. Conclusion The serum concentration of ICAM-1 and E-selectin waselevated significantly in patients with AMI Successful reperfusion therapy can reduce the increased serumconcentration.

DTC患者术后首次行大剂量131I治疗中维生素E对腮腺功能的影响

目的探讨术后首次大剂量131I治疗中,预先口服维生素E对腮腺的保护作用和对分化型甲状腺癌(differentiated thyroid cancer,DTC)患者腮腺功能的影响。方法选取2020年9月—2021年9月于牡丹江医学院附属红旗医院就诊的DTC术后患者40例,随机分为两组,A组为大剂量对照组,B组为大剂量观察组。B组的患者需于131I治疗前1周至131I治疗后1个月口服维生素E,A组不做特殊处理。对比131I治疗前后腮腺排泌分数(EF)、排泌率(ER)、摄取分数(UF)及摄取指数(UI)的变化。结果A组治疗后左腮腺ER值(51.09±5.62)%、EF值(51.78±5.77)%、右腮腺ER值(50.50±4.51)%及EF值(50.05±3.89)%均小于治疗前,差异有统计学意义(t=3.630、2.728、2.257、2.509,P<0.05);治疗前B组左右腮腺UI、UF值大于A组,差异有统计学意义(P<0.05)。结论DTC患者术后首次接受大剂量131I治疗时,可能会损伤腮腺功能的排泌功能,此时预先给予维生素E干预可以在一定程度上预防腮腺功能损伤。

二氢卟吩e_6的合成及其光敏化力和肿瘤光生物活性

由蚕沙叶绿素粗品 ,经酸碱降解反应制得二氢卟吩 e6 (1) ;并测定了 1在 D2 O中对 NADPH光氧化作用的敏化效应和对小鼠 S1 80 肉瘤的光动力损伤作用。初步试验结果表明 :1在非细胞体系内的光敏化力和对小鼠 S1 80 肉瘤的光动力疗效均优于参比药物血卟啉衍生物 (HPD)

前列腺素E1辅助治疗轻中度急性胰腺炎的临床分析

目的对比观察前列腺素E1在治疗急性胰腺炎(AP)中的临床疗效和安全性。方法前瞻性研究2014年5月-2015年1月吉林大学第一医院收治的轻中度AP患者80例,随机分为2组。对照组44例行胰腺炎常规综合治疗,试验组36例在常规治疗基础上加用前列腺素E1。比较2组患者腹部症状消失时间、血尿淀粉酶、血清脂肪酶、C反应蛋白、降钙素原降至正常水平的时间。计量资料组间比较采用独立样本t检验;计数资料组间比较采用χ2检验或Fisher精确检验。结果 2组血淀粉酶、C反应蛋白、中性粒细胞百分比恢复正常值的时间及住院费用间差异均有统计学意义(P值分别为0.041、0.030、0.012、0.026)。前列腺素E1可明显加速缓解腹痛、腹胀,快速降低血淀粉酶、C反应蛋白和中性粒细胞百分比;缩短住院时间,减少住院费用。结论前列腺素E1在治疗胰腺炎中具有良好的临床疗效、安全性好,可作为胰腺炎药物综合治疗的辅助用药选择。

慢性乙型肝炎患者抗病毒治疗前后HBeAg特异性T细胞应答特征研究

目的研究慢性乙型肝炎(CHB)患者抗病毒治疗前后T细胞对HBV特异性抗原蛋白(HBeAg)的免疫应答特征。方法分别收集22例慢性乙型肝炎患者抗病毒治疗前、治疗后3月、6月和12月的外周血,以HBeAg蛋白刺激外周血单个核细胞,采用酶联免疫斑点技术(ELISPOT)检测产生IFN-γ的HBeAg特异性T细胞的频率和强度。结果 1)CHB患者抗病毒治疗前和治疗后3月、6月、12月总的T细胞反应频率分别为31.8%(7/22)、50.0%(11/22)、77.3%(17/22)和95.5%(21/22),治疗后12月反应频率明显高于治疗前和治疗后3月(P<0.05),治疗后6月反应频率明显高于治疗前(P<0.05),核苷类似物治疗组与干扰素治疗组治疗后T细胞反应频率均无明显差异(P>0.05)。2)治疗后12月T细胞的反应强度明显高于治疗前、治疗后3月及治疗后6月(P<0.05)。核苷类似物治疗组与干扰素治疗组均分别得出上述相同的结果。3)将患者T细胞的反应强度与HBV DNA载量(取对数值表示)做Spearman秩相关分析,rs=-0.186<0,P=0.041,P<0.05,认为患者T细胞对HBeAg蛋白的反应强度与HBV DNA载量存在负相关关系。结论 HBeAg可以刺激CHB患者产生特异性T细胞应答,且随着抗病毒治疗时间的延长,患者HBeAg特异性T细胞的应答频率和应答强度均有所增强,且与血清HBV DNA水平呈负相关关系。